Achieve Life Sciences, Inc.

As of July 31, 2017, Achieve Life Sciences, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics and a 1-year stock return of -22.74%, significantly underperforming the S&P 500.

As of June 9, 2025, the market trend is mildly bearish due to daily moving averages and weekly Dow Theory indicating bearish momentum, despite some mildly bullish signals from the MACD and strong recent returns.

As of March 2022, the management team of Achieve Life Sciences, Inc. includes Executive Chairman Richard Stewart, CEO John Bencich, Directors Scott Cormack, Donald Joseph, Martin Mattingly, Jay Moyes, and Independent Director H. Stewart Parker, who oversee the company's strategic direction and operations.

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company focused on developing cytisine for smoking cessation. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $103.36 million.

As of Jun 18, Achieve Life Sciences, Inc. has a market capitalization of 103.36 million, with net sales of 0.00 million and a net profit of -46.16 million over the last four quarters. The company reported shareholder's funds of 20.90 million and total assets of 38.63 million as of Dec 24.